Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782168 · ClinicalTrials.gov registry record
Plasma Concentration of Biological Markers in Placental Abruption
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03782168: Clinical Trial study, sponsored by University of Arkansas.
NCT03782168 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03782168 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.
Primary Outcome
Determine quantitatively the level of placental-derived MPs which may be altered in 10 subjects with PA compared to 10 matched control subjects.
Interventions
- OTHER There is no other intervention, only clinical treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2021-08-01 |
Why NCT03782168 stopped before completion
NCT03782168 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There is no other intervention, only clinical treatment. is the first listed.
NCT03782168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03782168 about?
NCT03782168 is a clinical study titled "Plasma Concentration of Biological Markers in Placental Abruption". This will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. Maternal blood samples will be taken at various points during the peripartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood...
What is the current status of trial NCT03782168?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2019-01-31. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT03782168?
The interventions under investigation include: There is no other intervention, only clinical treatment. (OTHER).
Who is sponsoring clinical trial NCT03782168?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI